Cantor Fitzgerald Boosts Longboard Pharmaceuticals (NASDAQ:LBPH) Price Target to $16.00

Longboard Pharmaceuticals (NASDAQ:LBPH – Get Rating) had its price target raised by Cantor Fitzgerald from $11.00 to $16.00 in a research report report published on Thursday, The Fly reports. Other research analysts have also issued reports about the company. Citigroup dropped their price target on Longboard Pharmaceuticals from $24.00 to $17.00 and set a buy […]

Related Keywords

,Hedge Funds Weigh In On Longboard Pharmaceuticals ,Longboard Pharmaceuticals Stock Down ,Blackrock Inc ,Citigroup ,Health Asset Management ,Bourgeon Capital Management ,Longboard Pharmaceuticals Company Profile ,Asset Management Inc ,Analyst Recommendations For Longboard Pharmaceuticals ,Longboard Pharmaceuticals Inc ,News Ratings For Longboard Pharmaceuticals Daily ,Cantor Fitzgerald ,Longboard Pharmaceuticals ,Get Rating ,Pharmaceuticals Stock Down ,Capital Management ,Management Inc ,Prosight Management ,Longboard Pharmaceuticals Daily ,Nasdaq Lbph ,Lbph ,Medical ,Boost Price Target ,